{"organizations": [], "uuid": "b099e0aeea49f0c1e3467ebf0ba58882620f179c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-dova-pharmaceuticals-inc-announces-proposed-offering-of-common-stock.html", "country": "US", "domain_rank": 767, "title": "Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-02-21T00:05:00.000+02:00", "replies_count": 0, "uuid": "b099e0aeea49f0c1e3467ebf0ba58882620f179c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/20/globe-newswire-dova-pharmaceuticals-inc-announces-proposed-offering-of-common-stock.html", "ord_in_thread": 0, "title": "Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock", "locations": [], "entities": {"persons": [{"name": "dova", "sentiment": "none"}], "locations": [{"name": "durham", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "dova pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "dova pharmaceuticals, inc", "sentiment": "neutral"}, {"name": "securities and exchange commission", "sentiment": "none"}, {"name": "jefferies llc", "sentiment": "none"}, {"name": "evercore group l.l.c.", "sentiment": "none"}, {"name": "j.p. morgan securities llc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DURHAM, N.C., Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the offering will be sold by Dova. In addition, Dova expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount.\nJ.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are serving as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.\nA registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.\nThe offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at 1-877-821-7388 or by email at Prospectus_Department@Jefferies.com ; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com .\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Dova\nDova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dovaâ€™s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.\nContacts\nMark W. Hahn\n(919) 338-7936\nmhahn@dova.com\nWestwicke Partners\nJohn Woolford\n(443) 213-0506\njohn.woolford@westwicke.com\nSource:Dova Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=aGNYNMOctXeBHTeaTm90axncmP5OSuu7nt2XHUuN-MopPyznLzWKxE1GCnccobYNc7a2nROAil3cvNzMFjurArCImWJpAb45dXpCsDMiZDQf9wkoi_LfZa_ahX9xvQ-OsI_IXHZCVjLif-j7CgwRow==", "https://www.globenewswire.com/Tracker?data=_Ihts_V2AEV6fSydfkZD8tUgCeLk4MYFdvKhSE-NRtZPQ1z3n5nHQLq0TlezP6x5C6CQgpNIzUlJUtXI2gy_ww==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/47d57cbc-f8e0-41d8-920c-7f703dc16f0c", "https://www.globenewswire.com/Tracker?data=gtAmdviZOEqFU6U-nGWEXdyHHQm3tfYJcgdTU9x_UqQLHqEDWjl20BrvMT_he7GVv0pqaHQGzGve1cXxRdXtgxKm0r_L0GvumqL15fW2lL83oRsUzxwduVAHCSb3Rd4W", "https://www.globenewswire.com/Tracker?data=TTEdiUwTiYYGnJHYDre1aBKnWOd05NtBxrlsqCK2wp9-5C1f4d6xexk3h6FFvIvHoXTJQJn-3trBUJKdJg8sXgBbHqn0FwORhsVN4j2x0JAVa0YiqPuyusBIbRwGXJNF"], "published": "2018-02-21T00:05:00.000+02:00", "crawled": "2018-02-21T00:11:12.008+02:00", "highlightTitle": ""}